Dr. Alison Birtle (GB) announced the successor trial to PeriOperative chemotherapy or sUrveillance in upper Tract urothelial cancer, also known as POUT (CRUK/11/027; NCT01993979, NIHR portfolio) which is POUT 2: Chemotherapy with or without immunotherapy following nephron-ureterectomy for upper tract urothelial cancer.
Read more: Editorial on POUT trail.